Please enable JS

Investors

Press Releases

 
Press Releases
  Date Title View
Oct 18, 2017
CAMBRIDGE, Mass., Oct. 18, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the third quarter ended September 30, 2017 before the U.S. financial markets open on Wednesday, November 1, 2017.    ...
Oct 2, 2017
CAMBRIDGE, Mass., Oct. 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the promotion of Dr. Ganesh Kaundinya to Chief Operating Officer. Dr. Kaundinya, who assumed his new position effective September 25, 2017, ...
Aug 30, 2017
CAMBRIDGE, Mass., Aug. 30, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it plans to provide a corporate overview, including an update on its collaboration with CSL for the development of M230, at the 2017 We...
Aug 2, 2017
$10M milestone payment from Sandoz earned for the second anniversary of Glatopa® 20 mg as the sole FDA-approved generic on the market for patients with relapsing forms of multiple sclerosis  Ended second quarter with a strong cash position of $457M  CAMBRIDGE, Mass., Aug. 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasd...
Jul 21, 2017
CAMBRIDGE, Mass., July 21, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) today announced that the jury in the District Court for the District of Massachusetts in Boston has issued its verdict finding that the Company's U.S. Patent No. 7,575,886, covering methods for the manufacturing of generic LOVENOX® (Enoxaparin Sod...
Jul 19, 2017
CAMBRIDGE, Mass., July 19, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, will release its financial results for the second quarter ended June 30, 2017 before the U.S. financial markets open on Wednesday, August 2, 2017.    M...
Jun 7, 2017
CAMBRIDGE, Mass., June 07, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will provide a corporate overview, including an update on the timing of regulatory submissions for marketing approval for M923, its ...
Jun 1, 2017
CAMBRIDGE, Mass., June 01, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Santiago Arroyo, M.D., Ph.D. as Chief Medical Officer and Senior Vice President, Development. "Santiago's deep under...
May 10, 2017
CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at two upcoming investor conferences. Bank of America Merrill Lynch 2017 Health Care Conference We...
May 2, 2017
--Company reports Glatopa® 20 mg product revenues of $23 million, a 58% increase over the same period in 2016-- --Ended the first quarter with a strong cash position of $434 million--CAMBRIDGE, Mass., May 02, 2017 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA) today reported its financial results for the first quarter end...
1
...
NextLast
= add release to Briefcase